Sinovac Slashes 2010 Revenue Guidance by One-Third

Sinovac Biotech lowered its financial guidance for 2010 by a full 33%, saying it now expects revenues to be $40 million to $45 million. Earlier, the company expected 2010 sales to fall in a $60-67 million range. The company blamed the shortfall on a vaccine scare in China, caused by media reports of severe side effects of a vaccine administered in Shanxi province. More details.... Stock Symbol: (NSDQ: SVA)